Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on April 13, 2017. The report discloses a corporate governance event: the promotion of Clayton D. Edwards to Chief Operating Officer (COO), effective immediately.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the internal promotion of Clayton D. Edwards from Senior Vice President of Operations to Chief Operating Officer. Mr. Edwards, who joined the company in August 2016, now oversees operations including pharmacy, production, dispensing, customer service, information technology, and quality.
Compensation and Employment Terms
- Base Salary: $273,000 annually.
- Cash Incentive: Target bonus equal to 50% of base salary, contingent on corporate and individual performance goals.
- Equity Grant: Option to purchase up to 45,000 shares of common stock.
- Vesting Schedule: 11,250 shares vest on the first anniversary of the grant date; the remaining shares vest ratably each quarter over the subsequent three years (fully vested on the fourth anniversary).
Risks and Contingencies
The filing states there are no family relationships between Mr. Edwards and other officers/directors, and no undisclosed arrangements regarding his appointment. No specific financial risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the exact grant date and fair market value of the stock on that date to determine the exercise price of the 45,000 options.
- Review the specific performance goals set by the Compensation Committee for the target cash incentive bonus.
- Confirm the impact of this leadership change on the company's operational strategy in subsequent quarterly reports (10-Q/10-K).